KCT0004324已完成未知
Phase 1/2a clinical trial for the evaluation of safety and efficacy of allogeneic NK cell (SMT-NK”) in combination with Pembrolizumab for patients with Gemcitabine-refractory biliary tract cancer
SMT Bio0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •1. A person who receives an explanation from the trial manager about the purpose, contents, and characteristics of the Investigational products for the clinical trial and is signed by the person, guardian or legal representative in the written informed consent.
- •2. Be =19 years of age on day of signing informed consent.
- •3. Histopathological or cytologic diagnosis of advanced adenocarcinoma of the biliary tract.
- •4. Have a performance status of =2 on the ECOG Performance Scale.
- •5. Patients who survival period is expected to be at least 3 months.
- •6. Patients who meet the following conditions:
- •ANC(Absolute Neutrophil Count) = 1,500/µL
- •Hemoglobin= 10 g/dL
- •Platelet> 100,000/µL
- •Serum BUN & Creatinine = 1.5 x upper limit of normal (ULN)
- •AST & ALT = 2.5 x upper limit of normal (ULN)
- •Bilirubin = 3mg/L
- •7. Patients who agreed to the allogeneic natural killer cells therapy separated from the family of the patient or healthy donor’s blood.
- •8. Patients have a negative serum or urine pregnancy test (HCG, human chorionic gonadotropin) within 72 hours prior to receiving the first dose of study medication and agreed to use 2 methods of contraception. The period of contraception is up to 6 months after the last administration of Pembrolizumab.
- •9. Patients who meet one or more of the following conditions.
- •Patients have at least 1% Combined Positive Score (*CPS)
- •PD-L1 expression detected on the tumor, as determined by**immunohistochemistry performed by a central laboratory.
- •*CPS = (number of PD-L1 positive tumor cells, lymphocytes,macrophage)/ (total number of viable tumor cells) X 100
- •**immunohistochemistry: IHC 22C3 pharmDx test
- •Patients who have a positive *MSI-H or **dMMR test.
- •MSI-high positive tumors analyzed by PCR.
- •dMMR positive tumors analyzed by immunohistochemical staining .
- •*MSI-H was measured by PCR, and positive finding when two or more unstable markers were detected in PCR for 5
- •microsatellite markers.
- •**dMMR is analyzed by immunohistochemical staining and positive when the discovery of one or more genes in
- •MLH1, MSH2, MSH6 and PMS2 staining is lost.
排除标准
- •1. Patients who have previous history of Immune deficiency or autoimmune disease that can be aggravated by immunotherapy(for example:Rheumatoid arthritis, systemic lupus erythematosus, vasculitis, multiple sclerosis, Crohn's disease, ulcerative colitis, adolescent-developed insulin-dependent diabetes mellitus).
- •2. Diagnosis of immunodeficiency or is receiving systemic steroid therapy.
- •3. Have with pneumonia, colitis, hepatitis, nephritis, endocrine disorders(for example: Pituitary gland, thyroid dysfunction, Type 1 diabetes, etc.) associated with immunodeficiency.
- •4. Other malignant tumors within 5 years before the study enrollment.
- •5. Previous history of anti-angiogenic agent treatment before the study enrollment.
- •6. Received chemotherapy not less than 4 weeks old before the first administration of investigational products.
- •7. Apparent myocardial infarction or uncontrolled arterial hypertension.
- •8. Serious allergic history.
- •9. Serious mental illness.
- •10. Female who are pregnant, breastfeeding or intending to become pregnant during the study period.
- •11. A person who participated in another clinical trial within 4 weeks prior to the start of the study(based on the date of signing the informed consent.).
- •12. Previously administrated Pembrolizumab and other anti-PD-1/PD-L1 agent.
- •13. Previously administrated natural killer cell.
- •14. Patients who did not resolve the adverse event of the drug administered 4 weeks prior to enrollment.
- •15. Previous history of active central nervous system (CNS) metastasis and/or carcinomatous meningitis.
- •16. Previous history of non-infectious pneumonia.
- •17. Previous history of Has an active infection requiring systemic therapy.
- •18. Previous historyof Human Immunodeficiency Virus (HIV).
- •19. Previous history of active Hepatitis B (e.g., HBsAg reactive), Hepatitis C,Active tuberculosis.
- •20. Have received a live vaccine within 4 weeks before the first administration of investigational products.
- •21. Hypersensitivity to Pembrolizumab additive.
研究者
相似试验
尚未招募
2 期
Ayurvedic management of hyperactive childreCTRI/2022/07/044380Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
尚未招募
3 期
Ayurveda Management Of Acute Excerbation Of Tamaka Shwasa(Bronchial Asthma) in ChildreCTRI/2023/08/056084SDM College of ayurveda and hospital Hassan
进行中（未招募）
1 期
A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastomaGlioblastomaEUCTR2014-004197-42-DEniversity Hospital of Ulm10
已完成
1 期
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent GlioblastomaC71GlioblastomaMalignant neoplasm of brainDRKS00022861niversitätsklinikum Ulm, Kliniken am oberen Eselsberg10
尚未招募
1 期
A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy SubjectsInflammatory and Immune System - Autoimmune diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonPrimary Biliary CholangitisACTRN12624000967583Parvus Therapeutics, Inc.36